Sec Form 4 Filing - Puissance Cross-Border Opportunities V LLC @ Tracon Pharmaceuticals, Inc. - 2018-11-29

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Puissance Cross-Border Opportunities V LLC 2. Issuer Name and Ticker or Trading Symbol Tracon Pharmaceuticals, Inc. [ TCON] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 950 THIRD AVENUE, 25TH FL 3. Date of Earliest Transaction (MM/DD/YY) 11/29/2018 (Street) NEW YORK, NY10022 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 11/29/2018 P 4,326 A $ 1.13 4,606,094 I ( 4 ) By funds Common Stock 11/29/2018 S 4,326 A $ 1.21 4,601,768 I ( 4 ) By funds Common Stock 4,601,768 I ( 1 ) By funds

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Warrants (right to buy) $ 2.7 03/27/2018 03/27/2024 Common Stock 4,601,768 4,601,768 I ( 2 ) ( 3 ) By funds

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Puissance Cross-Border Opportunities V LLC 950 THIRD AVENUE 25TH FL NEW YORK, NY10022 X Puissance Cross-Border Opportunities IV LLC 950 THIRD AVENUE 25TH FL NEW YORK, NY10022 X Puissance Life Science Opportunities Fund VI 950 THIRD AVENUE FL 25 NEW YORK, NY10022 X Puissance Capital Management LP 950 THIRD AVENUE, 25TH FLOOR NEW YORK, NY10022 X Puissance Capital Management (GP) LLC 950 THIRD AVENUE 25TH FLOOR NEW YORK, NY10022 X Puissance Capital Fund (GP) LLC 950 THIRD AVENUE 25TH FLOOR NEW YORK, NY10022 X Wang Theodore T C/O PUISSANCE CAPITAL MANAGEMENT LP 950 THIRD AVENUE, 25TH FLOOR NEW YORK, NY10022 X X Signatures Theodore T. Wang 12/03/2018 Signature of Reporting Person Date Puissance Cross-Border Opportunities V LLC, By: Puissance Capital Fund (GP) LLC, its managing member, By: Theodore T. Wang 12/03/2018 Signature of Reporting Person Date Puissance Cross-Border Opportunities IV LLC, By: Puissance Capital Fund (GP) LLC, its managing member, By: Theodore T. Wang 12/03/2018 Signature of Reporting Person Date Puissance Life Science Opportunities Fund VI, By: Puissance Capital Fund (GP) LLC, its managing member, By: Theodore T. Wang 12/03/2018 Signature of Reporting Person Date Puissance Capital Fund (GP) LLC, By: Theodore T. Wang, Managing Member 12/03/2018 Signature of Reporting Person Date Puissance Capital Management LP, By: Puissance Capital Management (GP) LLC, its general partner, By: Theodore T. Wang, Managing Member 12/03/2018 Signature of Reporting Person Date Puissance Capital Management (GP) LLC, By: Theodore Wang, Managing Member 12/03/2018 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Consists of: 2,831,857 Shares directly owned by Puissance Cross-Border Opportunities V LLC; 1,769,911 Shares directly owned Puissance Cross-Border Opportunities IV LLC. ( 2 )Consists of: 2,831,857 Warrants directly owned by Puissance Cross-Border Opportunities V LLC; 1,769,911 Warrants directly owned Puissance Cross-Border Opportunities IV LLC. ( 3 )Puissance Capital Fund (GP) LLC serves as the managing member of Puissance Cross-Border Opportunities V LLC and Puissance Cross-Border Opportunities IV LLC and may be deemed to beneficially own these shares. Puissance Capital Management LP serves as the investment manager of Puissance Cross-Border Opportunities V LLC and Puissance Cross-Border Opportunities IV LLC and may be deemed to beneficially own these shares. Puissance Capital Management (GP) LLC serves as the general partner to Puissance Capital Management LP and may be deemed to beneficially own these shares. Theodore T. Wang serves as the managing member of Puissance Capital Fund (GP) LLC and Puissance Capital Management (GP) LLC and may be deemed to beneficially own these shares. ( 4 )The purchase and sale of 4,326 shares of Common Stock were under the fund Puissance Life Science Opportunities Fund VI.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.